
MedTech Executive Boston Scientific @bsccardiology. Air Force Veteran @AF_Academy Alum, @babson MBA Alum and ✈️ Enthusiast. 💯%HAPA🇺🇸🇯🇵Opinions are my own
Minnesota, USA
Joined August 2021
- Tweets286
- Following993
- Followers551
- Likes4.2K
Brian Mottola retweeted
New data just presented at #TCT2026!
WOLVERINE™ Cutting Balloon delivered ⬆️ greater lumen gain and ⬇️ less residual plaque at lower balloon pressures, while achieving comparable final MSA to NC balloon preparation. This study suggests more effective plaque modification and vessel preparation.
Learn more about WOLVERINE: qrco.de/bh5Ras
WOLVERINE™ Coronary Cutting Balloon™ Indications, Safety and Warnings: qrco.de/WOLVERINE
Brian Mottola retweeted
Not all IVL performs the same in nodular calcium.
SEISMIQ™ 4CE achieved a 6.7 mm^2 median MSA in FRACTURE IDE OCT Sub-Study, compared with 5.7 mm^2 reported for Shockwave C2 in Disrupt CAD III/IV OCT Sub-Studies.*
🔗Explore the data: qrco.de/bh5aDc
*Results from different clinical investigations are not directly comparable. Information provided for educational purposes only.
CAUTION: Investigational device. Limited by U.S. law to investigational use only. Not available for sale.
Brian Mottola retweeted
Presented at #TCT2026, Paclitaxel DCBs demonstrated significantly superior drug availability in tissue through all time points. AGENT™ DCB efficiently delivers sustained arterial drug through 120 days, despite a 33-43% lower drug load vs. other PTX DCBs.
Learn more about AGENT: qrco.de/bh5BIE
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
Brian Mottola retweeted
The doors are open at #TCT2026! Visit the Tech Suite at the Boston Scientific Engagement Hub to get a closer look at our technologies, connect with our team, and explore our interventional cardiology portfolio.
See what’s happening: qrco.de/bh1ecO
Brian Mottola retweeted
Every lesion type presents a different challenge.
ROTAPRO™ Rotational Atherectomy System helps reduce plaque burden from routine to complex across a range of calcified lesion types.
Learn more: qrco.de/bh18RE
ROTAPRO™ System - Indications, Safety, and Warnings: qrco.de/ROTAPRO
Brian Mottola retweeted
At #TCT2026, AGENT™ takes center stage with long-term evidence in complex patients.
From new study insights to engaging symposia, we’re bringing innovation and energy to this year’s meeting.
📅Be sure to mark these events as a priority and see how AGENT is helping shape what’s next in coronary care. 🔗qrco.de/bh1ecO
Brian Mottola retweeted
SEISMIQ™ 4CE gets its name from four coronary emitters. Pronounced “force”, 4CE is designed to deliver 360° of acoustic pressure at each emitter station, as part of a system built with visibility, control and deliverability in mind.
Explore the FRACTURE IDE Trial data: qrco.de/bh4MRx
Brian Mottola retweeted
Choose the DCB with proven safety.
Real-world data from the AGENT IDE trial demonstrated AGENT™ DCB had 0% stent thrombosis through 2 years. 🔗See the data behind AGENT: qrco.de/bh1Wmg
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
Brian Mottola retweeted
Not all coronary DCBs are backed by the same depth of evidence. AGENT™ DCB has been extensively studied, in highly complex patient populations.
🌎Globally, the device has been studied in over 16,000 patients and has a large body of U.S. real-world safety data available.
Explore the evidence behind AGENT: qrco.de/bh1Wmg
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
Brian Mottola retweeted
How much clinical evidence is behind your coronary DCB?
AGENT™ DCB:
📊 12,337 U.S. real world AGENT DCB patients studied.
Selution SLR™ DEB:
📊 No published U.S. real-world patient data.
AGENT DCB is backed by evidence at scale. See the AGENT™ difference: qrco.de/bguZu2
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
Brian Mottola retweeted
What do the FRACTURE IDE trial results tell us about SEISMIQ™ 4CE (pronounced “force”) Coronary Intravascular Lithotripsy Catheter?
At #EuroPCR2026, Dr. Margaret McEntegart and Dr. Evald Christiansen discussed the study findings, imaging-guided PCI, and the questions that remain as clinicians look toward real-world experience with laser-based IVL.
Watch the full interview. ▶️ qrco.de/bgzwB4
CAUTION: Investigational device. Limited by US law to investigational use only. Not available for sale.
Brian Mottola retweeted
Consistent data. Excellent real-world outcomes.
AGENT™ DCB continues to demonstrate consistent safety data in real-world practice. With in-patient hospital safety outcomes comparable to DES (drug-eluting stent) in complex ISR and 0% stent thrombosis through 2 years, AGENT has proven clinical performance.
Learn more about the data behind AGENT: qrco.de/bgyWxf
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
Brian Mottola retweeted
AGENT™ DCB is the most proven coronary DCB in the U.S. with statistical superiority to POBA at 1-year in AGENT IDE trial. Recent data demonstrated consistent results at 3 years with 28% risk reduction in TLF.
AGENT DCB: Evidence that earns confidence: qrco.de/bguZzk
AGENT™ Drug-Coated Balloon Indications, Safety, and Warnings: qrco.de/AGENT1
Brian Mottola retweeted
Treating severely calcified coronary lesions remains one of the biggest challenges in PCI.
Hear physicians share their experience with SEISMIQ™ 4CE Coronary Intravascular Lithotripsy (IVL) Catheter in the FRACTURE IDE Trial.
Explore the data: qrco.de/bgtL3I
CAUTION: Investigational device. Limited by US law to investigational use only. Not available for sale.
Brian Mottola retweeted
Let IVUS guide your strategy.
Hear Drs. @Nyalborgesmd, @ESHLOF, and @jbspadoni share their perspectives on what true IVUS-guided PCI looks like, and how using imaging helps improve your PCI strategy for better patient outcomes.
Learn more: qrco.de/bgqBEI
Brian Mottola retweeted
Coming out of #EuroPCR2026, the data continues to reinforce that calcium modification is not one-size-fits-all. The ShortCUT IVUS sub-analysis showed WOLVERINE™ Cutting Balloon delivered clinically meaningful MSA, similar stent expansion, and better procedural cost vs. Shockwave IVL. Learn more about WOLVERINE™: qrco.de/bgodiw
WOLVERINE™ Coronary Cutting Balloon™ Indications, Safety and Warnings: qrco.de/WOLVERINE
Brian Mottola retweeted
IVUS-used vs. IVUS-guided.
Hear fresh insights from the IVUS-CHIP trial at ACC.26, as Drs. @Nyalborgesmd, @ESHLOF, and @jbspadoni share expert perspectives and how these findings play an important role in the clinical application of IVUS data.
Dive into the data: qrco.de/bgoLT4












